Does Melatonin Produce Drowsiness?
Yes, melatonin does produce drowsiness as a documented adverse effect, though this occurs primarily when taken at higher doses or during daytime hours. 1, 2, 3
Primary Effects and Mechanism
Melatonin functions primarily as a chronobiotic (circadian rhythm regulator) rather than a traditional sedative-hypnotic. The American Academy of Sleep Medicine guidelines distinguish between melatonin's phase-shifting effects and its direct soporific (sleep-inducing) properties 1. The drowsiness effect is dose-dependent—higher doses (above 5 mg) are more likely to produce direct sedative effects, while lower doses (0.5-3 mg) work predominantly through circadian regulation 1.
Clinical Evidence for Drowsiness
Drowsiness is the most commonly reported adverse effect of melatonin, occurring in approximately 28.8% of users in recent observational data 2. A systematic review and meta-analysis found that daytime sleepiness was the most frequent adverse event at 1.66% in controlled trials, though this likely underestimates real-world occurrence 4. Higher-dose melatonin (≥10 mg) significantly increased the risk of adverse events including drowsiness, headache, and dizziness compared to placebo (Rate Ratio 1.40, p < .001) 3.
Important Clinical Distinctions
The timing of administration critically determines whether drowsiness is therapeutic or problematic:
- When taken 1-2 hours before bedtime: The drowsiness effect is desirable and contributes to sleep onset 1, 5
- When taken during daytime hours: Drowsiness becomes an unwanted adverse effect 1
- Residual morning effects: Unlike traditional benzodiazepine hypnotics, melatonin typically does not produce morning "hangover" symptoms or residual daytime sedation when taken appropriately at night 6
Dosing Considerations
The American Academy of Sleep Medicine notes that timing is more important than dose for circadian effects, but dose does matter for sedative effects 1. Studies in medically ill patients using mean doses of 5.4 mg demonstrated improved sleep onset and quality without producing drowsiness or early-morning hangover symptoms when taken at bedtime 6. This apparent contradiction is explained by the fact that drowsiness occurring at the intended sleep time is therapeutic, not adverse.
Safety Profile Context
Despite drowsiness being the most common side effect, melatonin maintains an excellent overall safety profile. The 2008 AASM guideline for chronic insomnia states that melatonin has "small effects on sleep latency, with little effect on wake after sleep onset or total sleep time" 7. More recent evidence confirms that only mild adverse effects occur, with no serious or life-threatening events reported in systematic reviews 4, 8.
Clinical Recommendations
For practitioners prescribing melatonin:
- Expect drowsiness as a common effect, particularly at doses >4 mg 2, 3
- Advise patients to take melatonin 1-2 hours before desired bedtime (approximately 6 PM for typical sleep schedules) to align drowsiness with sleep onset 5
- Warn against daytime use or activities requiring alertness shortly after administration 1
- Start with lower doses (0.5-3 mg) if circadian regulation is the primary goal and sedation is undesired 1
- Consider immediate-release formulations over prolonged-release if sleep onset is the target, as these show better efficacy 9
The drowsiness effect should be framed to patients as an expected therapeutic response when melatonin is used correctly for sleep disorders, rather than purely as an adverse effect.